Positron Emission Tomography in Renal Cell Carcinoma
Journal Title: Üroonkoloji Bülteni - Year 2018, Vol 17, Issue 2
Abstract
Renal cell carcinoma is the most common solid kidney tumor. Conventional methods such as computed tomography and magnetic resonance imaging are usually chosen for diagnosis, staging, and evaluating recurrence and treatment response. However, the sensitivity of these methods is limited in each indication. For this reason, metabolic evaluation with positron emission tomography has an important value in most solid tumors. However, the role of 18-fluorine-fluorodeoxyglucose (18F-FDG), which is the most commonly used positron emission tomography (PET) radiopharmaceutical, is limited in the evaluation of primary kidney lesions due to urinary excretion. Therefore, new radiopharmaceuticals with no or limited urinary excretion have been developed. In this paper, the application of PET imaging with the widely used 18F-FDG and the newly developed fluorothymidine and gallium-68/18F prostate-specific membrane antigen in renal cell carcinoma are reviewed.
Authors and Affiliations
Cigdem Soydal, Yüksel Ürün
Keywords
Related Articles
- EP ID EP379768
- DOI 10.4274/uob.946
- Views 92
- Downloads 0
Robotic-assisted Laparoscopic Prostatectomy: Initial Experience of 267 Cases
Objective: To present our experience of 267 consecutive patients treated with robotic-assisted laparoscopic prostatectomy (RALP) and assess the perioperative and postoperative outcomes. Materials and Methods: Materials a...
The Incidence of Prostate Adenocarcinoma in Patients Who Underwent Cystoprostatectomy for Invasive Baldder Cancer and Histopathological Examination
Objective: It was aimed to evaluate the incidence of prostate adenocarcinoma in patients treated by cystoprostatectomy for invasive bladder urothelial carcinoma and to demonstrate the histopathological features of prosta...
Incidentally Found Paratesticular Rhabdomyosarcoma: Case Report
Paratesticular rhabdomyosarcomas (RMS) constitute 7% of all RMS. Paratesticular RMS are malignant tumors and although many of them are seen in children and adolescents, 24% of them are seen in adults. A patient in the ol...
Risk Adaptive Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
Muscle invasive bladder cancer (MIBC) is an aggressive tumor with a high rate of early systemic dissemination. The main treatment for MIBC is still radical cystectomy and lymph node dissection. Survival rates for 5-year...
Immunotherapy in Prostate Cancer
In recent years, immunotherapy has become an important treatment alternative in the treatment of many cancers. Research on immunotherapy in prostate cancer has been accelerated by obtaining Food and Drug Administration (...